A thorough update is presented by the Guest Editors on the diagnosis, treatment, and management of Barrett’s Esophagus. Not only do they address the most pertinent clinical issues like screening, biomarkers, surveillance, therapeutics, and predictors of disease progression but they present state of the art material on therapeutic/treatment modalities like EMR, ESD, and ablative therapy. Further, articles are presented on epidemiology, molecular pathogensis, and cost-analysis studies so that the reader will come away with a comprehensive update on Barrett’s Esophagus.
1. Cover image - p. 1 2. Title page - p. 2 3. Table of Contents - p. 3 4. Copyright - p. 4 5. Contributors - p. 5 6. Forthcoming Issues - p. 9 7. Foreword: Barrett’s Esophagus - p. 10 8. Preface: Barrett’s Esophagus: New Insights and Progress - p. 11 9. Epidemiology of Barrett’s Esophagus and Esophageal Adenocarcinoma - p. 12 10. Molecular Pathogenesis of Barrett Esophagus - p. 28 11. Role of Obesity in the Pathogenesis and Progression of Barrett’s Esophagus - p. 35 12. Screening for Barrett’s Esophagus - p. 44 13. Surveillance in Barrett’s Esophagus - p. 51 14. Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett’s Esophagus - p. 59 15. Endoscopic Mucosal Resection and Endoscopic Submucosal Dissection for Endoscopic Therapy of Barrett’s Esophagus-related Neoplasia - p. 69 16. Ablative Endoscopic Therapies for Barrett’s-Esophagus-Related Neoplasia - p. 78 17. Challenges with Endoscopic Therapy for Barrett’s Esophagus - p. 86 18. Biomarkers in Barrett’s Esophagus - p. 96 19. Chemoprevention in Barrett’s Esophagus - p. 106 20. The Effect of Proton Pump Inhibitors on Barrett’s Esophagus - p. 119 21. Cost-Analyses Studies in Barrett’s Esophagus - p. 125 22. Advanced Imaging in Barrett's Esophagus - p. 132 23. Surgical Management of Barrett’s Esophagus - p. 143 24. Genetic and Epigenetic Alterations in Barrett’s Esophagus and Esophageal Adenocarcinoma - p. 151 25. Index - p. 161
No hay muestra disponible
No hay ficha técnica disponible
A thorough update is presented by the Guest Editors on the diagnosis, treatment, and management of Barrett’s Esophagus. Not only do they address the most pertinent clinical issues like screening, biomarkers, surveillance, therapeutics, and predictors of disease progression but they present state of the art material on therapeutic/treatment modalities like EMR, ESD, and ablative therapy. Further, articles are presented on epidemiology, molecular pathogensis, and cost-analysis studies so that the reader will come away with a comprehensive update on Barrett’s Esophagus.
1. Cover image - p. 1 2. Title page - p. 2 3. Table of Contents - p. 3 4. Copyright - p. 4 5. Contributors - p. 5 6. Forthcoming Issues - p. 9 7. Foreword: Barrett’s Esophagus - p. 10 8. Preface: Barrett’s Esophagus: New Insights and Progress - p. 11 9. Epidemiology of Barrett’s Esophagus and Esophageal Adenocarcinoma - p. 12 10. Molecular Pathogenesis of Barrett Esophagus - p. 28 11. Role of Obesity in the Pathogenesis and Progression of Barrett’s Esophagus - p. 35 12. Screening for Barrett’s Esophagus - p. 44 13. Surveillance in Barrett’s Esophagus - p. 51 14. Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett’s Esophagus - p. 59 15. Endoscopic Mucosal Resection and Endoscopic Submucosal Dissection for Endoscopic Therapy of Barrett’s Esophagus-related Neoplasia - p. 69 16. Ablative Endoscopic Therapies for Barrett’s-Esophagus-Related Neoplasia - p. 78 17. Challenges with Endoscopic Therapy for Barrett’s Esophagus - p. 86 18. Biomarkers in Barrett’s Esophagus - p. 96 19. Chemoprevention in Barrett’s Esophagus - p. 106 20. The Effect of Proton Pump Inhibitors on Barrett’s Esophagus - p. 119 21. Cost-Analyses Studies in Barrett’s Esophagus - p. 125 22. Advanced Imaging in Barrett's Esophagus - p. 132 23. Surgical Management of Barrett’s Esophagus - p. 143 24. Genetic and Epigenetic Alterations in Barrett’s Esophagus and Esophageal Adenocarcinoma - p. 151 25. Index - p. 161
No hay muestra disponible
No hay ficha técnica disponible
